The global precision biotics market is on track to nearly double in five years, reaching $9.26 billion by 2031 from $4.91 billion in 2026 — a compound annual growth rate of 13.5% — according to a new forecast from MarketsandMarkets. The projection signals a structural shift in how the supplement and functional food industries are approaching gut health: away from broad-spectrum probiotic blends and toward strain-specific, evidence-backed formulations tailored to defined physiological outcomes.
What's Driving Growth
Several converging forces are accelerating the market. Advances in shotgun metagenomics and microbiome sequencing have made it commercially viable to identify and validate strains with targeted mechanisms of action — a prerequisite for precision positioning. At the same time, consumer demand for personalized nutrition has pushed finished-goods brands to move beyond generic "digestive support" structure-function claims toward more differentiated, clinically grounded messaging. Rising awareness of the gut-brain axis, gut-immune crosstalk, and the microbiome's role in metabolic health has expanded the category's addressable consumer base well beyond legacy digestive-health shoppers.
Next-generation probiotics (NGPs) — including species such as Akkermansia muciniphila, Faecalibacterium prausnitzii, and Christensenellaceae relatives that were previously difficult to culture and stabilize — represent the fastest-growing type segment in the report. NGPs command premium ingredient pricing and require more sophisticated manufacturing controls, including anaerobic fermentation and advanced encapsulation to deliver viable CFU counts at the finished-formulation level. For ingredient suppliers and co-manufacturers, the NGP segment represents both a technical barrier to entry and a meaningful margin opportunity compared with commodity Lactobacillus and Bifidobacterium strains.
Regional and Channel Outlook
Asia Pacific is flagged as the fastest-growing regional market, consistent with broader trends in the functional foods and beverages space, where markets including China, South Korea, Japan, and India are investing heavily in domestic microbiome research and nutraceutical infrastructure. The region's combination of government-backed health initiatives, a large aging population, and high consumer receptivity to science-forward positioning makes it a priority market for ingredient suppliers seeking distribution partners.
In North America and Europe — still the largest revenue bases — precision biotics are penetrating beyond traditional dietary supplement channels into medical nutrition and clinical settings, where a growing number of registered dietitians and gastroenterologists are recommending strain-specific probiotic protocols for conditions including irritable bowel syndrome, antibiotic-associated diarrhea, and post-bariatric gut rehabilitation. The GLP-1 weight-management wave has added another tailwind, as clinicians and brands look to address gut dysbiosis and nutrient absorption changes in patients on semaglutide and tirzepatide therapies.
For operators evaluating precision biotics as a formulation or brand differentiation strategy, the MarketsandMarkets data underscore that this is no longer a niche science story — it is a mainstream commercial trajectory with a decade of investment momentum behind it.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
